Basal Tumours in Bladder Cancer, Response to chemoTherapy

Conditions:   Bladder Cancer;   Chemotherapy Effect Intervention:   Combination Product: neoadjuvant chemotherapy with cisplatine Sponsors:   University Hospital, Rouen;   Institut Curie;   APHP Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Authors: Albisinni S, Veccia A, Aoun F, Diamand R, Esperto F, Porpiglia F, Roumeguère T, De Nunzio C Abstract INTRODUCTION: Robotic assisted radical cystectomy (RARC) is gaining popularity worldwide, although its enthusiastic implementation is supported mainly by retrospective studies. Aim of this review is to compare the outcomes of RARC and open radical cystectomy (ORC) in the setting of randomized controlled trials (RCTs). EVIDENCE ACQUISITION: Three search engines (PubMed, Embase®, and Web of Science) were queried up to January 1, 2019. Studies selections followed The Preferred Reporting Items fo...
Source: Minerva Urologica e Nefrologica - Category: Urology & Nephrology Tags: Minerva Urol Nefrol Source Type: research
ConclusionsUsing lncRNA expression profiles, we identified a biologically distinct subgroup of luminal-papillary MIBC with a favorable prognosis. These data suggest that lncRNAs provide additional information for higher-resolution subtyping, potentially improving precision patient management.
Source: Genome Medicine - Category: Genetics & Stem Cells Source Type: research
Abstract OBJECTIVES: Overexpression of aurora kinase A (AURKA) confers a poor prognosis in patients with urothelial carcinoma of the bladder. The prognostic value of high aurora kinase B (AURKB) expression in local bladder cancer is not well defined, and whether the prognostic value of either AURKA or AURKB is affected by the use of chemotherapy is unknown. We sought to characterize the impact of high AURKA and AURKB expression on clinical outcome in patients with muscle-invasive bladder cancer (MIBC) who received neoadjuvant chemotherapy (NAC). MATERIALS AND METHODS: Immunohistochemistry for AURKA and AURKB ...
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
"Watch and Wait" for complete clinical response after neoadjuvant chemoradiotherapy for rectal cancer. Minerva Chir. 2019 Sep 30;: Authors: Peacock O, Chang GJ Abstract The management of rectal cancer has evolved substantially over recent decades, becoming increasingly complex. This was once a disease associated with high mortality and limited treatment options that typically necessitated a permanent colostomy, has now become a model for multidisciplinary evaluation, treatment and surgical advancement. Despite advances in the rates of total mesorectal excision, decreased local recurrence and ...
Source: Minerva Chirurgica - Category: Surgery Tags: Minerva Chir Source Type: research
ConclusionsThe results demonstrate that robotic-assisted TME for patients with rectal cancer after neoadjuvant CCRT (concurrent chemoradiotherapy) is effective and for patient with tumor invaded to bladder, prostate or uterus, neoadjuvant chemotherapy is a safe and effective way for organ-preserving instead of salvage surgery.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: Neoadjuvant chemotherapy utilization continues to slowly increase in patients with MIBC. Patients with variant histology lag behind in terms of receiving NAC but appear to derive as much benefit as patients with pure urothelial cell bladder cancer.
Source: Indian Journal of Urology - Category: Urology & Nephrology Authors: Source Type: research
ConclusionsWe propose a set of QIs for both NMIBC and MIBC based on established clinical guidelines and the available literature. Measurement of these QIs could aid in improvement and benchmarking of optimal care of bladder cancer.Patient summaryAfter a systematic review of existing guidelines and literature, a panel of experts has recommended a set of quality indicators that can help providers and patients measure and strive towards optimal outcomes for bladder cancer care.
Source: European Urology - Category: Urology & Nephrology Source Type: research
Conditions:   Bladder Cancer;   Chemotherapy Effect Intervention:   Combination Product: neoadjuvant chemotherapy with cisplatine Sponsors:   University Hospital, Rouen;   Institut Curie;   APHP Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bladder Cancer | Cancer | Cancer & Oncology | Chemotherapy | Hospitals | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Research